Compass Pathways IPO marks the first liquidity event for WPSS.
WPSS invested in Compass Pathway’s series B alongside Founders Fund and McQuade/Otsuka. Compass Pathways IPO marks the first liquidity event for WPSS.
New York City, Oct. 01, 2020 (GLOBE NEWSWIRE) — WPSS Investments, a pioneer biotech Venture Capital fund focused on brain health and psychedelic medicine, celebrates the successful IPO of its portfolio company Compass Pathways.
On September 18th, 2020 Compass Pathways was listed (NASDAQ:CMPS, ISIN:US20451W1018), making it the first psychedelic company to be listed on a U.S. exchange. CMPS´s price per share has surged more than 100% since its initial listing price of 17USD, turning it into the most valuable and first unicorn psychedelic medicine company in the world.
Compass Pathways, was co-founded several years ago by